Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a change in the estimated GFR (a decline of ≥ 30 ml per minute per 1.73 m(2) if the initial estimated GFR was ≥ 60 ml per minute per 1.73 m(2) or a decline of ≥ 50% if the initial estimated GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD), or death. The secondary renal end point was the first occurrence of a decline in the estimated GFR or ESRD. Safety outcomes included mortality, hyperkalemia, and acute kidney injury. Results The study was stopped early owing to safety concerns. Among 1448 randomly assigned patients with a median follow-up of 2.2 years, there were 152 primary end-point events in the monotherapy group and 132 in the combination-therapy group (hazard ratio with combination therapy, 0.88; 95% confidence interval [CI], 0.70 to 1.12; P=0.30). A trend toward a benefit from combination therapy with respect to the secondary end point (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P=0.10) decreased with time (P=0.02 for nonproportionality). There was no benefit with respect to mortality (hazard ratio for death, 1.04; 95% CI, 0.73 to 1.49; P=0.75) or cardiovascular events. Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001). Conclusions Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; VA NEPHRON-D ClinicalTrials.gov number, NCT00555217.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Two clinical trials studied the combinations of ACE inhibitors and ARBs and found no benefits on CVD or CKD, and the medication combination had higher adverse event rates (hyperkalemia and/or AKI) (87,88).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [88]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Clinical Physiology of Acid-Base and Electrolyte Disorders
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-176_8 · Cited by 1,156
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Research works printed but not linked: 2
- National Kidney Foundation, 2002, Am J Kidney Dis, 30, S1
- International Conference on Harmonisation, 1995, Fed Regist, 60, 11284
Cited by
Items 301–400 of 1,001
Esteras, R., Pérez-Gómez, M. V., Rodríguez-Osorio, L., Ortíz, A., & Fernández‐Fernández, B. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098615589905 · Cited by 51
Heerspink, H. J. L., Persson, F., Brenner, B. M., Chaturvedi, N., Brunel, P., McMurray, J. J. V., Desai, A. S., Solomon, S. D., Pfeffer, M. A., PARVING, H.-H. D., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00469-6 · Cited by 52
Lullo, L. D., Lavalle, C., Scatena, A., Mariani, M. V., Ronco, C., & Bellasi, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123992 · Cited by 55
Beernink, J. M., van Mil, D., Laverman, G. D., Heerspink, H. J. L., & Gansevoort, R. T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16359 · Cited by 58
Hsu, F.-Y., Lin, F., Ou, H., Huang, S.-H., & Wang, C. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000477946 · Cited by 49
Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice
Nicola, L. D., Lullo, L. D., Paoletti, E., Cupisti, A., & Bianchi, S. (2018) · Journal of Nephrology · doi:10.1007/s40620-018-0502-6 · Cited by 55
Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?
Lavoz, C., Rayego‐Mateos, S., Orejudo, M., Opazo-Ríos, L., Marchant, V. A., Márquez‐Expósito, L., Tejera‐Muñoz, A., Navarro‐González, J. F., Droguett, A., Ortíz, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010272 · Cited by 51
Malek, V., Suryavanshi, S. V., Sharma, N., Kulkarni, Y. A., Mulay, S. R., & Gaikwad, A. B. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_50 · Cited by 51
Mineralocorticoid Antagonism and Diabetic Kidney Disease
Lytvyn, Y., Godoy, L. C., Scholtes, R. A., van Raalte, D. H., & Cherney, D. Z. I. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1123-8 · Cited by 52
New Therapies for the Treatment of Renal Fibrosis
Liu, F., & Zhuang, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_31 · Cited by 51
Morales, E., Cravedi, P., & Manrique, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.653634 · Cited by 56
RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus
Kumar, V., Agarwal, S., Saboo, B., & Makkar, B. M. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01143-7 · Cited by 58
Sarafidis, P. A., Iatridi, F., Ferro, C. J., Alexandrou, M. E., Fernández‐Fernández, B., Kanbay, M., Mallamaci, F., Nistor, I., Rossignol, P., Wanner, C., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad139 · Cited by 48
Ruiz‐Hurtado, G., Condezo‐Hoyos, L., Pulido-Olmo, H., Aránguez, I., González, M. C., Arribas, S. M., Cerezo, C., Segura, J., Praga, M., Fernández‐Alfonso, M. S., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000292 · Cited by 51
Managing hypertension in type 2 diabetes mellitus
Horr, S. E., & Nissen, S. E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.001 · Cited by 49
Pofi, R., Fiore, D., Gaetano, R. D., Panio, G., Gianfrilli, D., Pozza, C., Barbagallo, F., Xiang, Y. K., Giannakakis, K., Morano, S., et al. (2017) · Scientific Reports · doi:10.1038/srep44584 · Cited by 48
Jun, M., Jardine, M. J., Perkovic, V., Pilard, Q., Billot, L., Rodgers, A., Rogers, K., & Gallagher, M. (2019) · PLOS ONE · doi:10.1371/journal.pone.0213192 · Cited by 45
Hyperkalemia in patients with chronic renal failure
Seliger, S. L. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz231 · Cited by 46
Self-citationUnmet need in diabetic nephropathy: failed drugs or trials?
de Zeeuw, D., & Heerspink, H. J. L. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30045-6 · Cited by 46
UK HARP-III Collaborative Group, Judge, P., Haynes, R., Herrington, W. G., Storey, B., Staplin, N., Bethel, A., Bowman, L., Brunskill, N., Cockwell, P., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw321 · Cited by 49
Guidelines for the management of hypertension in CKD patients: where do we stand in 2024?
Theodorakopoulou, M. P., Ortíz, A., Fernández‐Fernández, B., Kanbay, M., Minutolo, R., & Sarafidis, P. A. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae278 · Cited by 56
Mega clinical trials which have shaped the RAS intervention clinical practice
Düsing, R. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716644131 · Cited by 47
He, C. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190611620.003.0028 · Cited by 44
Global cardiovascular protection in chronic kidney disease
Ruiz‐Hurtado, G., Sarafidis, P. A., Fernández‐Alfonso, M. S., Waeber, B., & Ruilope, L. M. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.48 · Cited by 45
Hypertension Management in Patients with Chronic Kidney Disease
Hebert, S. A., & Ibrahim, H. N. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1119 · Cited by 73
Luo, X., Xu, J., Zhou, S., Xue, C., Chen, Z., & Mao, Z. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000205 · Cited by 45
Whitlock, R. H., Leon, S. J., Manacsa, H., Askin, N., Rigatto, C., Fatoba, S., Farag, Y. M. K., & Tangri, N. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad101 · Cited by 49
Slowing the Progression of Diabetic Kidney Disease
Blazek, O., & Bakris, G. L. (2023) · Cells · doi:10.3390/cells12151975 · Cited by 47
Joumaa, J. P., Raffoul, A., Sarkis, C., Chatrieh, E., Zaidan, S., Attieh, P., Harb, F., Azar, S. T., & Ghadieh, H. E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030727 · Cited by 47
Kang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 84
Diabetic nephropathy: What does the future hold?
Montero, R., Covic, A. C., Gnudi, L., & Goldsmith, D. J. A. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-1121-y · Cited by 45
An Overview on Renoprotective Effects of Thymoquinone
Shaterzadeh‐Yazdi, H., Noorbakhsh, M. F., Samarghandian, S., & Farkhondeh, T. (2018) · Kidney Diseases · doi:10.1159/000486829 · Cited by 43
Siew, E. D., Parr, S. K., Abdel-Kader, K., Perkins, A. M., Greevy, R. A., Vincz, A. J., Denton, J., Wilson, O. D., Hung, A. M., Ikizler, T. A., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.08.022 · Cited by 41
Sarafidis, P. A., Ortíz, A., Ferro, C. J., Halimi, J., Kreutz, R. H., Mallamaci, F., Mancia, G., & Wanner, C. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002776 · Cited by 45
MicroRNAs and their delivery in diabetic fibrosis
Wonnacott, A., Denby, L., Coward, R. J., Fraser, D. J., & Bowen, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114045 · Cited by 45
Present and Future in the Treatment of Diabetic Kidney Disease
Quiroga, B., Arroyo, D., & de Arriba, G. (2015) · Journal of Diabetes Research · doi:10.1155/2015/801348 · Cited by 40
Carnosine treatment in combination with ACE inhibition in diabetic rats
Peters, V., Riedl, E., Braunagel, M., Höger, S., Hauske, S. J., Pfister, F., Zschocke, J., Lanthaler, B., Benck, U., Hammes, H., et al. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.09.005 · Cited by 42
Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade
Palevsky, P. M., Zhang, J. H., Seliger, S. L., Emanuele, N., Fried, L. F., & Study, F. T. V. N.-D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03470316 · Cited by 44
Self-citationAlbuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View
Fried, L. F., & Lewis, J. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10681014 · Cited by 42
Self-citationSchneider, M. P., Hilgers, K. F., Schmid, M. C., Hübner, S., Nadal, J., Seitz, D., Busch, M., Haller, H. G., Köttgen, A., Kronenberg, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202604 · Cited by 45
Preventing and treating kidney disease in patients with type 2 diabetes
Delanaye, P., & Scheen, A. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1551362 · Cited by 47
Hypertensive kidney disease: true epidemic or rare disease?
Stompór, T. P., & Perkowska‐Ptasińska, A. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15150 · Cited by 50
Ren, F., Tang, L., Cai, Y., Yuan, X. Y., Huang, W., Luo, L., Zhou, J. F., & Zheng, Y. (2015) · Renal Failure · doi:10.3109/0886022x.2015.1012995 · Cited by 41
Fried, L. F., Schmedt, N., Folkerts, K., Bowrin, K., Raad, H., Batech, M., & Kovesdy, C. P. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac140 · Cited by 45
Self-citationGaddy, A. R., Elrggal, M. E., Madariaga, H. M., Kelly, A., Lerma, E. V., & Colbert, G. B. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101848 · Cited by 44
Keap1 hypomorphism protects against ischemic and obstructive kidney disease
Tan, R. J., Chartoumpekis, D. V., Rush, B. M., Zhou, D. F., Fu, H., Kensler, T. W., & Liu, Y. (2016) · Scientific Reports · doi:10.1038/srep36185 · Cited by 40
Sternlicht, H., & Bakris, G. L. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.08.001 · Cited by 46
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes
Garlo, K. G., White, W. B., Bakris, G. L., Zannad, F. M., Wilson, C., Kupfer, S., Vaduganathan, M., Morrow, D. A., Cannon, C. P., & Charytan, D. M. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05280517 · Cited by 40
Saglimbene, V., Palmer, S. C., Ruospo, M., Natale, P., Maione, A., Nicolucci, A., Vecchio, M., Tognoni, G., Craig, J. C., Pellegrini, F., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018040443 · Cited by 39
Sarafidis, P., Papadopoulos, C. E., Kamperidis, V., Giannakoulas, G., & Doumas, M. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17005 · Cited by 39
Lerma, E., White, W. B., & Bakris, G. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2022.2060598 · Cited by 39
Longitudinal TNFR1 and TNFR2 and Kidney Outcomes: Results from AASK and VA NEPHRON-D
Chen, T. K., Coca, S. G., Estrella, M. M., Appel, L. J., Coresh, J., Thiessen‐Philbrook, H., Obeid, W., Fried, L. F., Heerspink, H. J. L., Ix, J. H., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021060735 · Cited by 41
Self-citationHyperkalemia in Diabetes Mellitus Setting
Goia-Nishide, K., Coregliano-Ring, L., & Rangel, É. B. (2022) · Diseases · doi:10.3390/diseases10020020 · Cited by 43
Capítulo 3 - Avaliação Clínica e Complementar
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160153 · Cited by 51
Kruse, B. C., & Vassar, M. B. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.10.007 · Cited by 39
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Sternlicht, H., & Bakris, G. L. (2016) · Blood Purification · doi:10.1159/000441264 · Cited by 45
Mitigating risk of aldosterone in diabetic kidney disease
Frimodt‐Møller, M., Persson, F., & Rossing, P. R. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000557 · Cited by 39
Longhitano, E., Calabrese, V., Casuscelli, C., Carlo, S. D., Maltese, S., Romeo, A., Calanna, M., Conti, G., & Santoro, D. (2024) · Medicina · doi:10.3390/medicina60111821 · Cited by 46
Therapies on the Horizon for Diabetic Kidney Disease
Khan, S. S., & Quaggin, S. E. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0685-3 · Cited by 41
Callera, G. E., Antunes, T. T., Corrêa, J. W. D. N., Moorman, D., Gutsol, A. A., He, Y., Cat, A. N. D., Briones, A. M., Montezano, A. C. I., Burns, K. D., et al. (2016) · Bioscience Reports · doi:10.1042/bsr20160344 · Cited by 38
Tamargo, J. L., Caballero, R., & Delpón, E. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6767-5 · Cited by 39
KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline
Kramer, H., Townsend, R. R., Griffin, K. A., Flynn, J. T., Weiner, D. E., Rocco, M. V., Choi, M. J., Weir, M. R., Chang, T. I., Agarwal, R., et al. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.01.007 · Cited by 38
Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease
Ali, S., Dave, N., Virani, S. S., & Navaneethan, S. D. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0794-6 · Cited by 40
Microalbuminuria and cardiorenal risk: old and new evidence in different populations
Márquez, D. F., Ruiz‐Hurtado, G., Segura, J., & Ruilope, L. M. (2019) · F1000Research · doi:10.12688/f1000research.17212.1 · Cited by 41
A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease
Vecchio, L. D., Beretta, A., Jovane, C., Peiti, S., & Genovesi, S. (2021) · Drugs · doi:10.1007/s40265-021-01573-3 · Cited by 41
Hypertension and the Role of Dietary Fiber
Nepali, P., Suresh, S., Pikale, G., Jhaveri, S., Avanthika, C., Bansal, M., Islam, R., & Chanpura, A. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101203 · Cited by 41
Mesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy
Paulini, J., Higuti, E., Bastos, R. M. C., Gomes, S. A., & Rangel, É. B. (2016) · Stem Cells International · doi:10.1155/2016/9521629 · Cited by 40
Yang, Q., Zheng, R., Wang, S., Zhu, J., Li, M., Wang, T., Zhao, Z., Xu, M., Lu, J., Chen, Y., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.20954 · Cited by 38
Chan, C. K. W., Szeto, C., Lee, L. K. C., Xiao, Y., Yin, B., Ding, X., Lee, T. W. Y., Lau, J. Y. W., & Choi, C. H. J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305662120 · Cited by 41
Baseline characteristics and enrichment results from the SONAR trial
Heerspink, H. J. L., Andress, D. L., Bakris, G. L., Brennan, J. J., Correa‐Rotter, R., Hou, F. F., Kitzman, D. W., Kohan, D. E., Makino, H., McMurray, J. J. V., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13315 · Cited by 36
SGLT2 inhibitors – a potential treatment for Alport syndrome
Mabillard, H. R., & Sayer, J. A. (2020) · Clinical Science · doi:10.1042/cs20191276 · Cited by 38
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
(2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.05.011 · Cited by 36
Agarwal, R., Pitt, B., Rossing, P. R., Anker, S. D., Filippatos, G. S., Ruilope, L. M., Kovesdy, C. P., Tuttle, K. R., Vaduganathan, M., Wanner, C., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.1505 · Cited by 36
Advances in treatment of hyperkalemia in chronic kidney disease
Sarafidis, P. A., Georgianos, P. I., & Bakris, G. L. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1083977 · Cited by 36
Hypertension in Minority Populations: New Guidelines and Emerging Concepts
Rodríguez, F., & Ferdinand, K. C. (2015) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.08.004 · Cited by 39
Chronic Kidney Disease in the Older Adult Patient with Diabetes
Ravender, R., Roumelioti, M., Schmidt, D. W., Unruh, M. L., & Argyropoulos, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020348 · Cited by 42
Wu, Y., Zhang, C., Guo, R., Wu, D., Shi, J., Li, L., Chu, Y., Yuan, X., & Gao, J. (2021) · Stem Cells International · doi:10.1155/2021/6620811 · Cited by 37
Viazzi, F. C., Bonino, B., Cappadona, F., & Pontremoli, R. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1435-5 · Cited by 36
Shen, L., Ghoshal, S., Sojoodi, M., Arora, G., Masia, R., Erstad, D. J., Ferriera, D. S., Li, Y., Wang, G., Lanuti, M. D., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201801699r · Cited by 35
Sarafidis, P. A., Schmieder, R. E., Burnier, M., Persu, A., Januszewicz, A., Halimi, J., Arıcı, M., Ortíz, A., Wanner, C., Mancia, G., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae041 · Cited by 35
Renin-Angiotensin-Aldosterone System Inhibition
Mercier, K., Smith, H. D., & Biederman, J. I. (2014) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2014.08.002 · Cited by 37
Toto, R. D. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017121317 · Cited by 33
Chen, Y., Yu, X.-Y., Chen, L., Vaziri, N. D., Ma, S., & Zhao, Y. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.06.012 · Cited by 35
Anderson, R. J., Bahn, G., Emanuele, N., Marks, J. B., Duckworth, W. C., & for the VADT Study Group (2014) · Diabetes Care · doi:10.2337/dc14-0284 · Cited by 33
Self-citationNassirpour, R., Raj, D., Townsend, R. R., & Argyropoulos, C. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.02.018 · Cited by 33
Wu, J., Shi, R., Lu, X., Ma, Y., & Cheng, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122661 · Cited by 32
Agrawal, H., Aggarwal, K. B., Littrell, R. L., Velagapudi, P., Turagam, M. K., Mittal, M., & Alpert, M. (2015) · Current Cardiology Reviews · doi:10.2174/1573403x1103150514155757 · Cited by 35
Zhang, X., Shi, Z., Liu, Q., Quan, H., & Cheng, X. (2019) · Medicine · doi:10.1097/md.0000000000015850 · Cited by 36
Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure
Grosman‐Rimon, L., Billia, F., Wright, E., Carasso, S., Elbaz‐Greener, G., Kachel, E., Rao, V. A., & Cherney, D. Z. I. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09860-8 · Cited by 36
Hadidi, S. E., Rosano, G. M. C., Tamargo, J. L., Agewall, S., Drexel, H., Kaski, J. C., Niessner, A., Lewis, B. S., Coats, A. J. S., & Savarese, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa108 · Cited by 36
Jiang, T., Wang, L., Ma, A., Wu, Y., Wu, Q., Wu, Q., Lu, J., & Zhong, T. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13515 · Cited by 32
DeFronzo, R. A., & Bakris, G. L. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14696 · Cited by 35
Capítulo 14 – Crise Hipertensiva
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160164 · Cited by 33
Wang, T., Gao, Y., Yue, R., Wang, X., Shi, Y., Xu, J., Wu, B., & Li, Y. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/2735714 · Cited by 42
Betts, K. A., Song, J., Faust, E., Yang, K., DU, Y., Kong, S. X., & Singh, R. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88807 · Cited by 39
Chen, D., Wu, J., & Li, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1055296 · Cited by 38
USP25 ameliorates diabetic nephropathy by inhibiting TRAF6-mediated inflammatory responses
Liu, B., Miao, X., Shen, J., Lou, L., Chen, K., Mei, F., Chen, M., Su, X., Du, X., Zhu, Z., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110877 · Cited by 35
Medication-Induced Nephrotoxicity in Older Patients
Fusco, S., Garasto, S., Corsonello, A., Vena, S., Mari, V., Gareri, P., Ruotolo, G., Luciani, F., Roncone, A., Maggio, M. G., et al. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666160406115959 · Cited by 37
Fogelfeld, L. A., Hart, P., Miernik, J., Ko, J., Calvin, D. J., Tahsin, B., Adhami, A., Mehrotra, R., & Fogg, L. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.11.019 · Cited by 31
Long Non-Coding RNA CASC2 Improves Diabetic Nephropathy by Inhibiting JNK Pathway
Yang, H., Kan, Q. E., Su, Y., & Man, H. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0629-9958 · Cited by 31
Metadata
- Authors
- Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., Reilly, R. F., Seliger, S. L., Warren, S. R., Watnick, S., Peduzzi, P., & Guarino, P.
- Affiliations
- Boston University (US)
- Loyola University Medical Center (US)
- VA Connecticut Healthcare System (US)
- University of New Mexico (US)
- University of Arizona (US)
- Ascension (US)
- University of Pittsburgh (US)
- VA North Texas Health Care System (US)
- University of Maryland, Baltimore (US)
- Portland VA Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-11-14
- Volume
- 369
- Issue
- 20
- Pages
- 1892-1903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2162368776
- Semantic Scholar
- 7e191f2ee9fe17b31623d78bf58b03d157e94654
- Cited by
- 1,169
- References
- 19
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 67 · 2023: 95 · 2022: 75 · 2021: 102 · 2020: 89 · 2019: 105 · 2018: 88 · 2017: 98 · 2016: 104 · 2015: 123 · 2014: 122 · 2013: 9
- FWCI
- 90.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, losartan, lisinopril, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes, estimated glomerular filtration rate decline, end-stage renal disease, albuminuria, hyperkalemia, acute kidney injury, drug safety, early trial termination, cardiovascular events, mortality, proteinuria, kidney disease progression
- MeSH terms
- Adult, Angiotensin-Converting Enzyme Inhibitors, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Lisinopril, Losartan, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.